Lupin receives approval from USFDA for Brexpiprazole Tablets
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
The Indian government will float a global tender in April 2023 to procure HPV vaccines.
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
The observations are procedural in nature
Expands robotics to 20+ specialities
Biocorp will receive an initial milestone payment this year
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
Spain’s renowned centre of excellence recognises importance of verifying radiosurgery plans ahead of patient treatment
Subscribe To Our Newsletter & Stay Updated